Introduction
============

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related death today. In the United States it ranks fourth, accounting for approximately 30,000 deaths per year \[[@b1]\]. Apart from surgery there is no effective therapy, and even most patients who had undergone tumour resection die within the first 3 years after surgery \[[@b2]\]. The main reason for this poor prognosis is local recurrence and/or the occurrence of distant metastases. Whereas the genetic and epigenetic changes of tumour epithelia in general have been investigated in great detail in the last decades \[[@b3]\], the contribution of tumour stroma during the natural history is still incomplete \[[@b4]\]. Stromal cells might revert a tumourigenic phenotype \[[@b5]\], but participation of stromal tissue during metastatic processes has also been described \[[@b6]\]. The stromal compartment of a tumour might also harbour genetic changes indicating a coevolutionary process of tumour epithelium and stroma compartment \[[@b7]\]. In PDAC, it has been demonstrated that radiation of stromal fibroblasts increase the invasiveness of PDAC \[[@b8], [@b9]\]. Several mediators of stromal epithelial interaction have been described \[[@b10]\], of which *TGF*-β takes part in the development of fibrotic changes within the stroma of pancreatic tissue \[[@b11]\]. Only recently the relevance of the Wnt signalling pathway in mediating stromal--epithelial interactions of tumours has been described \[[@b12]\]. However, in contrast to many other solid tumours the canonical Wnt signal transduction pathway is rarely activated in PDAC, since translocation of β-catenin to the nucleus is seldom observed \[[@b13], [@b14]\]. Recently, various research groups have applied DNA-microarray technology to identify differentially expressed genes in PDAC for new diagnostic and therapeutic approaches \[[@b15]--[@b20]\]. Most of these studies were performed on whole tissue samples which contain different cell types and focused on the gene expression differences of the epithelial compartment of the tumour. Those expression profiles cannot be attributed to one cell type and thus, microdissection is the method of choice to generate a more precise picture of gene expression changes in a specific cell type. We have established microdissection and microarray-based gene expression profiling in PDAC epithelia cells \[[@b21]\], and we have now compared now gene expression profiles from tumour-associated stromal tissue with expression profiles from benign stromal tissue using the Affymetrix U133 GeneChip set. Since there are only very few stromal cells adjacent to normal pancreatic ducts, we analysed stromal cells from the fibrotic tissue of chronic pancreatitis a benign tissue remodelling process of the pancreas \[[@b22]\]. We identified genes whose expression levels differed significantly between stroma from PDAC and from chronic pancreatitis. Within this set of genes, we detected an over-representation of genes encoding Wnt signalling molecules within the PDAC stroma and we were able to validate the overexpression of WNT5a suggesting that the non-canonical Wnt signalling cascade is activated.

Material and methods
====================

Patients and tissues
--------------------

Freshly frozen tissue samples of PDACs (n = 11) were obtained from surgical specimens from patients who underwent surgery at the Department of Visceral-, Thoracic- and Vascular-Surgery, University Hospital Carl Gustav Carus, Technical University of Dresden and the Department of General Surgery, University of Kiel, Germany, between 1996 and 2003. Chronic pancreatitis specimens (n = 9) were obtained from patients who underwent pancreatic resection. Prior to surgery, all patients had signed an informed consent form that had been approved by the local ethics committee. Immediately after surgical removal the specimens were sectioned and microscopically evaluated. Suitable samples of tumour tissue or normal tissue were snap frozen in liquid nitrogen and stored at −80°C until further processing.

Microdissection
---------------

Microdissection was performed in the laboratory of the Institute of Pathology, University Schleswig-Holstein Campus Kiel, Kiel, Germany as already described \[[@b21]\]. In brief, frozen tissue specimens were cut into 10 μm sections and slides were immediately fixed in 70% ethanol. The sections were briefly stained with haematoxylin and eosin and coverslipped. Suitable areas for microdissection without visible neoplastic cell contamination were marked on these slides and served as a template for microdissection. The estimated cellularity was approx. 10,000--11,000 cells per microdissected sample and the purity of the dissections was approx. 90%. For comparison, we included the gene expression data from our previous study of microdissected tumour epithelia \[[@b21]\] and seven additional epithelia samples (two normal, five PDAC).

Cell culture
------------

The cell lines CAPAN2, BxPC3, CAPAN1, ASPC1, COLO357, MiaPaCa2, Panc1, Panc89, PT45, PancTUI, Kif5, F13 \[[@b23]\] and immortalized primary stellate cells \[[@b24]\] were cultured in RPMI 1640 supplemented with 10% foetal bovine serum, 2 mM glutamine, non-essential amino acids (5 ml/l), penicillin (10,000 units/ml), and streptomycin (10 mg/ml) and passaged before they reached confluency. All cell culture materials were obtained from Invitrogen, Karlsruhe, Germany. 1.5 × 10^5^ Panc89 and 1.5 × 10^5^ Kif5 cells (human mesenchymal cells) were cocultured and separated by a 0.2 μm membrane (Becton Dickinson Labware, NJ, USA). After reaching confluence (48 hrs), the cells were trypsinized and transferred to new vessels to coculture cells for 60 additional hrs. Following trypsinization of the cells RNA isolation was performed using a Micro-to-Midi Total RNA Purification System (Invitrogen, Paisley, UK) according to the manufacturer\'s instruction.

RNA preparation and array hybridization
---------------------------------------

RNA preparation and array hybridization was performed as described earlier \[[@b21]\]. In brief, Poly A^†^-RNA from the microdissected surgical specimens and cell cultures was prepared using a PolyATtract 1000 kit (Promega, Heidelberg, Germany). For each sample the cDNA synthesis and repetitive *in vitro* transcription were performed three times. First-strand cDNA synthesis was initiated using the Affymetrix T7-oligo-dT promotor-primer combination at 0.1 mM. After second-strand cDNA synthesis the *in vitro* transcription was performed using Ambion\'s Megascript kit (Ambion, Huntington, UK), as recommended by the manufacturer. From the generated aRNA a new first-strand synthesis was initiated using 0.025 mM of a random hexamer as primer. After completion, the second-strand synthesis was performed using the Affymetrix T7-oligo-dT promotor-primer combination as primer at a concentration of 0.1 mM. A second *in vitro* transcription was performed and then the procedure was repeated one additional time. During the last *in vitro* transcription, biotin-labelled nucleotides were incorporated into the aRNA, as recommended by the Affymetrix protocol. Hybridization and detection of the labelled aRNA on the U133 A/B Affymetrix GeneChip set (Affymetrix, Santa Clara, CA, USA) were performed according to Affymetrix instructions.

Gene expression analysis
------------------------

The U133 A/B Affymetrix GeneChip set utilized in this study consists of more than 44,000 probe sets. The Cel Files obtained from the Affymetrix MAS 5.0 software were loaded into dChip2006 (www.dchip.org), normalized and expression values were calculated using the PM/MM model \[[@b25]\]. To minimize the noise within the gene expression data set we used only the probe sets that displayed an intensity value of greater than 120 in more than 15% of the chips analysed and in which average intensity were below 4000. The cut-off of 120 for the intensity value was derived from the intensity values from the bacterial control probe sets for the Bacillus subtilis genes dapB, lys, pheA, thrC and trpE within the data set. Only 1% of those probe sets revealed intensity values above 120, thus limiting the probability of false positives due to random fluctuation of the background intensities. The expression values were exported and further explored using SAM (http://www-stat.stanford.edu/∼tibs/SAM/) \[[@b26]\] and Excel (Microsoft, Seattle, WA, USA). We scored genes as differentially expressed if they met the following criteria: a fold change \>2 and a q-value ≤5%. Identification of probe sets expression overexpressed only in pancreatic tumour stroma was done using dChip (cut-off: fold change \>4 and *P*-value \< 0.05) by comparing the expression of tumour stroma samples (group 1) with chronic pan-creatitis stroma, tumour epithelia and normal epithelia samples (group 2).

Quantitative RT-PCR
-------------------

The aRNA from the second amplification cycle, as stated above, was reversely transcribed into cDNA. 1 ng of cDNA was used for a TaqMan assay (Applied Biosystems, Weiterstadt, Germany). The genes were amplified with the TaqMan Universal PCR Master Mix according to the manufacturer\'s instructions, with an ABI PRISM 5700 Sequence Detection System using gene specific primers and probes. Gene expression was quantified by the comparative cT-Method, normalizing cT-values to a housekeeping gene (β-*actin* or *G6PDH*) and calculating the relative expression values \[[@b27]\] using the following primers: G6PDH forward: 5′-acgtgatgcagaaccac-ctactg; G6PDH reverse: 5′- acgacggctgcaaaagtggcg-3′; SFRP1 forward: 5′-gatgcaggaggctcaggtgat-3′; SFRP1 reverse: 5′-tgtcctgtgtatctgctggcaac-3′; WNT5a forward: 5′-taggcacgaaagcacaggtc-3′; WNT5a reverse: 5′-cacggcatctctctttcacca-3′; CXCL14 forward: 5′-ctgtgatggcgagacaaatg-3′; CXCL14 reverse: 5′-gttgggaacctcacatgctt-3′; β-actin forward: 5′-aatgc-tatcacctcccctgtgt-3′ and β-actin reverse: 5′-aagccaccccacttctctctaa-3′.

For the cocultivation experiments total RNA was prepared and the reverse transcription was performed using Superscript II reverse transcrip-tase (Invitrogen) and random hexamer primers (Applied Biosystems, Foster City, CA, USA) according to the manufacture\'s suggestions. The subsequent quantitative PCR reaction was conducted using SYBR green Super Mix (Bio-Rad Laboratories GmbH, Munich, Germany), gene specific primers and the following PCR conditions: 95°C, 5 min. (single step); 95°C, 30 sec.; 60°C, 45 sec.; 72°C, 70 sec. (40 cycles). The fluorescence was determined by Bio-Rad\'s Opticon PCR-System.

Immunohistochemistry
--------------------

For immunohistochemistry, 5 μm sections were routinely prepared using sialinized slides (superfrost slides from Menzel Gl‰ser, Braunschweig, Germany). Immunohistochemistry for WNT5a and SFRP1 was performed using the streptavidin-biotin-peroxidase method as described previously \[[@b28]\]. Antigen retrieval was carried out in a microwave oven (250 W for 30 min. in a citrate solution pH 6.0). The primary antibodies used were a mouse poly-clonal antibody against the WNT5a protein (clone GT15034; 10 μg/ml; Neuromics, Northfield, MN and sc-23698, Santa Cruz, CA, USA), a polyclonal antiserum generated in rabbits with a synthesized peptide corresponding to amino acids 285-299 of the human SFRP1 protein (1:50) \[[@b29]\] and a goat antibody against the CXCL14 protein (AF866; 1:50; R&D Systems, Minneapolis, MN, USA). As negative control specimens were incubated without the primary antibody. Afterwards, the slides were briefly counterstained with haematoxylin and eosin. For the negative control, the primary antibody was omitted. The staining intensity was evaluated for each sample semi-quantitatively as absent, weak, moderate or strong by one pathologist (A.H. A.W. or G.K.) and by C.P. without knowledge of the histopathologic and molecular data. For the analysis of immunohistochemical staining of tumour and the adjacent normal tissue we employed the Wilcoxon Rank test.

Results
=======

Gene expression analysis of stromal tissues
-------------------------------------------

Using microdissection, stromal tissue adjacent to the tumour from 11 patients with PDAC and stromal tissue from nine patients with chronic pancreatitis were obtained and compared. The combination of fold change (cut-off: \>2) and SAM q-value (cut-off: ≤5%) analysis yielded 331 differentially expressed probe sets from 316 genes. In total, 61 genes were under-expressed and 255 were overexpressed in the stromal tissue of PDAC ([Table 1](#tbl1){ref-type="table"}).

###### 

The 100 most differentially expressed genes in PDAC stromal tissue

  Representative public ID   Affymetrix probeset ID   Fold change (TS/CP)   Gene symbol       Gene title
  -------------------------- ------------------------ --------------------- ----------------- ----------------------------------------------------------------------------
  Up-regulated                                                                                
  NM_005498                  218261_at                22.67                 *AP1M2*           Adaptor-related protein complex 1, mu 2 subunit
  ***NM_004887***            ***218002_s\_at***       **13.25**             **CXCL14**        ***Chemokine (C-X-C motif) ligand 14***
  AI739132                   229479_at                8.97                  *LOC646324*       Hypothetical LOC646324
  NM_001854                  204320_at                8.04                  *COL11A1*         Collagen, type XI, α 1
  NM_005940                  203878_s\_at             7.40                  *MMP11*           Matrix metallopeptidase 11 (stromelysin 3)
  NM_007036                  208394_x\_at             6.55                  *ESM1*            Endothelial cell-specific molecule 1
  BC006361                   211050_x\_at             6.21                  *DKFZP434B2016*   Similar to hypothetical protein LOC284701
  AF352728                   221701_s\_at             6.09                  *STRA6*           Stimulated by retinoic acid gene 6 homologue (mouse)
  AU156710                   227123_at                5.68                  *RAB3B*           RAB3B, member RAS oncogene family
  AB033025                   212942_s\_at             5.25                  *KIAA1199*        KIAA1199
  AI822137                   230135_at                5.17                  *EST*             CDNA FLJ42405 fis, clone ASTRO3000474
  BE327661                   240649_at                4.89                  *EST*             Transcribed locus
  AA741296                   238812_at                4.69                  *ZFAND6*          Zinc finger, AN1-type domain 6
  M86849                     223278_at                4.64                  *GJB2*            Gap junction protein, β 2, 26 kD (connexin 26)
  AW972824                   244765_at                4.63                  *DUSP27*          Dual specificity phosphatase 27 (putative)
  AK025453                   228656_at                4.33                  *PROX1*           Prospero-related homeobox 1
  AW301806                   217580_x\_at             4.33                  *ARL6IP2*         ADP-ribosylation factor-like 6 interacting protein 2
  NM_006587                  220356_at                4.18                  *CORIN*           Corin, serine peptidase
  AI376003                   205941_s\_at             4.08                  *COL10A1*         Collagen, type X, α 1(Schmid metaphyseal chondrodysplasia)
  AF288571                   221558_s\_at             3.90                  *LEF1*            Lymphoid enhancer-binding factor 1
  AA382425                   232109_at                3.90                  *UBXD3*           UBX domain containing 3
  T10030                     228210_at                3.87                  *NXPH3*           Neurexophilin 3
  NM_003248                  204776_at                3.84                  *THBS4*           Thrombospondin 4
  M57707                     204188_s\_at             3.78                  *RARG*            Retinoic acid receptor, γ
  NM_003326                  207426_s\_at             3.76                  *TNFSF4*          Tumour necrosis factor (ligand) superfamily, member 4
  AB051466                   232327_at                3.73                  *THSD7B*          Thrombospondin, type I, domain containing 7B
  AL136559                   223536_at                3.61                  *PSD2*            Pleckstrin and Sec7 domain containing 2
  NM_012261                  219463_at                3.60                  *C20orf103*       Chromosome 20 open-reading frame 103
  M31159                     210095_s\_at             3.50                  *IGFBP3*          Insulin-like growth factor-binding protein 3
  AW296153                   235540_at                3.50                  *EST*             ---
  AI206039                   231187_at                3.41                  *SLC28A1*         Solute carrier family 28 (sodium-coupled nucleoside transporter), member 1
  W74476                     226997_at                3.41                  *EST*             CDNA FLJ10196 fis, clone HEMBA1004776
  AB032931                   223229_at                3.34                  *UBE2T*           Ubiquitin-conjugating enzyme E2T (putative)
  AW593143                   205134_s\_at             3.32                  *NUFIP1*          Nuclear fragile X mental retardation protein interacting protein 1
  NM_016931                  219773_at                3.30                  *NOX4*            NADPH oxidase 4
  AI081522                   244486_at                3.29                  *PINK1*           PTEN-induced putative kinase 1
  AB015329                   215138_s\_at             3.27                  *KIAA1026*        Kazrin
  AI378647                   230147_at                3.26                  *F2RL2*           Coagulation factor II (thrombin) receptor-like 2
  AW664964                   230493_at                3.21                  *TMEM46*          Transmembrane protein 46
  AK024472                   226530_at                3.15                  *BMF*             Bcl2 modifying factor
  NM_001845                  211981_at                3.14                  *COL4A1*          Collagen, type IV, α 1
  BF476080                   229779_at                3.13                  *COL4A4*          Collagen, type IV, α 4
  NM_021161                  220727_at                3.10                  *KCNK10*          Potassium channel, subfamily K, member 10
  NM_002381                  206091_at                3.09                  *MATN3*           Matrilin 3
  AI222435                   230319_at                3.07                  *C4orf31*         Chromosome 4 open-reading frame 31
  U09716                     203294_s\_at             3.04                  *LMAN1*           Lectin, mannose-binding, 1
  U03115                     217060_at                3.01                  *EST*             T cell receptor b chain variable region (TCRB) mRNA, 5′ end
  AI742057                   226702_at                2.99                  *LOC129607*       Hypothetical protein LOC129607
  AA012950                   239126_at                2.98                  *C19orf23*        Chromosome 19 open reading frame 23
  NM_003427                  207494_s\_at             2.97                  *ZNF76*           Zinc finger protein 76 (expressed in testis)
  Down-regulated                                                                              
  NM_019598                  220782_x\_at             0.04                  *KLK12*           Kallikrein-related peptidase 12
  NM_000273                  206696_at                0.05                  *GPR143*          G protein-coupled receptor 143
  NM_005867                  207258_at                0.11                  *DSCR4*           Down syndrome critical region gene 4
  AI090768                   224808_s\_at             0.13                  *C7orf20*         Chromosome 7 open reading frame 20
  NM_006461                  203145_at                0.14                  *SPAG5*           Sperm-associated antigen 5
  AF105378                   228206_at                0.15                  *HS3ST4*          Heparan sulphate (glucosamine) 3-O-sulfotransferase 4
  N53051                     229378_at                0.16                  *STOX1*           Storkhead box 1
  NM_017748                  218655_s\_at             0.17                  *CCDC49*          Coiled-coil domain containing 49
  BE273906                   238980_x\_at             0.18                  *C17orf56*        Chromosome 17 open reading frame 56
  NM_002580                  205815_at                0.18                  *REG3A*           Regenerating islet-derived 3 alpha
  AA419275                   224970_at                0.20                  *NFIA*            nuclear factor I/A
  U05598                     209699_x\_at             0.20                  *AKR1C2*          Aldo-keto reductase family 1, member C2
  M25915                     208792_s\_at             0.22                  *CLU*             Clusterin
  BF439728                   238317_x\_at             0.25                  *RBMS1*           RNA binding motif, single-stranded interacting protein 1
  NM_001458                  207876_s\_at             0.27                  *FLNC*            Filamin C, γ (actin-binding protein 280)
  NM_001353                  204151_x\_at             0.27                  *AKR1C1*          Aldo-keto reductase family 1, member C1
  M13452                     212089_at                0.28                  *LMNA*            Lamin A/C
  NM_006179                  231785_at                0.28                  *NTF5*            Neurotrophin 5 (neurotrophin 4/5)
  NM_003277                  204482_at                0.30                  *CLDN5*           Claudin 5 (transmembrane protein deleted in velocardiofacial syndrome)
  NM_001937                  207977_s\_at             0.31                  *DPT*             Dermatopontin
  AW157077                   203197_s\_at             0.31                  *C1orf123*        Chromosome 1 open reading frame 123
  AB056476                   224339_s\_at             0.32                  *ANGPTL1*         Angiopoietin-like 1
  BE646573                   223217_s\_at             0.33                  *NFKBIZ*          Nuclear factor of κ light polypeptide gene enhancer in B cells inhibitor
  NM_002178                  203851_at                0.35                  *IGFBP6*          Insulin-like growth factor-binding protein 6
  AA780381                   215498_s\_at             0.35                  *MAP2K3*          Mitogen-activated protein kinase kinase 3
  AA194312                   227086_at                0.36                  *HIRA*            HIR histone cell cycle regulation defective homologue A (S. cerevisiae)
  AL353132                   217021_at                0.37                  *CYB5A*           Cytochrome b5 type A (microsomal)
  NM_020190                  218162_at                0.37                  *OLFML3*          Olfactomedin-like 3
  NM_001159                  205083_at                0.39                  *AOX1*            Aldehyde oxidase 1
  NM_000504                  205620_at                0.39                  *F10*             Coagulation factor X
  AW779917                   230003_at                0.39                  *EST*             Transcribed locus
  AV757441                   238675_x\_at             0.40                  *EST*             ---
  AK022266                   233817_at                0.40                  *NBPF10*          Neuroblastoma breakpoint family, member 10
  AF109161                   209357_at                0.40                  *CITED2*          Cbp/p300-interacting transactivator
  NM_014057                  218730_s\_at             0.40                  *OGN*             Osteoglycin (osteoinductive factor, mimecan)
  NM_006086                  202154_x\_at             0.41                  *TUBB3*           Tubulin, β 3
  ***NM_003012***            ***202037_s\_at***       ***0.42***            ***SFRP1***       ***secreted frizzled-related protein 1***
  AW157094                   209291_at                0.42                  *ID4*             Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein
  AB028976                   212845_at                0.42                  *SAMD4A*          Sterile a motif domain containing 4A
  AI830227                   222065_s\_at             0.42                  *FLII*            Flightless I homologue (Drosophila)
  M24317                     209612_s\_at             0.43                  *ADH1B*           Alcohol dehydrogenase IB (class I), β polypeptide
  AF043290                   209447_at                0.43                  *SYNE1*           Spectrin repeat containing, nuclear envelope 1
  AI989530                   227197_at                0.45                  *SGEF*            Src homology 3 domain-containing guanine nucleotide exchange factor
  NM_001449                  201540_at                0.45                  *FHL1*            Four and a half LIM domains 1
  AK023795                   222162_s\_at             0.45                  *ADAMTS1*         ADAM metallopeptidase with thrombospondin type 1 motif, 1
  AB011538                   203812_at                0.46                  *EST*             CDNA clone IMAGE:5922621
  BE967532                   203636_at                0.46                  *MID1*            Midline 1 (Opitz/BBB syndrome)
  NM_001801                  204154_at                0.46                  *CDO1*            Cysteine dioxygenase, type I
  U36764                     208756_at                0.47                  *EIF3S2*          Eukaryotic translation initiation factor 3, subunit 2 β, 36 kD
  AL136694                   223938_at                0.47                  *C1orf49*         Chromosome 1 open-reading frame 49

Gene selected for further validation are marked in bold and italic. TS, tumour stroma; CP, stroma of chronic pancreatitis. The complete table is available as supplemental data.

Hierarchical clustering of the stromal tissue samples using the 331 probe sets revealed two major clusters of stromal tissue of chronic pancreatitis and of PDAC ([Fig. 1A](#fig01){ref-type="fig"}).

![(**A**) Hierarchical clustering of the stromal tissue samples using the identified differentially expressed genes. (**B**) Hierarchical clustering of pancreatic tissues and cell lines using the 205 probe sets identified asdifferentially expressed between tumour stroma and all other primary tissues from the 331 probe set. Probe set within the black lines are highly expressed in tumour stroma and the genes of this cluster are depicted on the right. (**C**) Heatmap of the expression of the 331 probe sets in the data set. Probe sets within the black line are highly expressed in cell lines and are depicted on the right. The cell line PT45 is the last column to the right in [Fig. 1**B** and **C**](#fig01){ref-type="fig"}.](jcmm0012-2823-f1){#fig01}

Identifcation of genes overexpressed in tumour stroma
-----------------------------------------------------

To identifiy genes highly expressed in pancreatic tumour stroma, we compared the expression of the 331 probe sets between pancreatic tumour stroma and other primary pancreatic tissues excluding pancreatic cell lines. 19 of the 331 probe sets representing 16 genes (including *CXCL14*, *COL10A1* and *COL11A1*) were up-regulated by a fold change of at least 4 ([Fig. 1B](#fig01){ref-type="fig"}).

Signal transduction pathway analysis of differentially expressed genes
----------------------------------------------------------------------

Using the FatiGO^†^ tool in conjunction with the KEGG database from the Babelomics web server, we were able to assign 45 out of the 316 differentially expressed genes to a KEGG pathway ([Fig. 2](#fig02){ref-type="fig"}) \[[@b30]\]. Interestingly, five overexpressed and one underexpressed genes were associated with the general Wnt signal transduction cascade indicating an activation of the pathway in PDAC stroma. Moreover, the KEGG pathway analysis showed that three genes of the Mitogen-activated protein kinases (MAPK) signalling pathway were underexpressed and one was overexpressed in PDAC stroma ([Fig. 2A and B](#fig02){ref-type="fig"}).

![(**A**) Association of the differentially expressed genes with KEGG signal transduction pathways. Green: genes underexpressed; red: genes overex-pressed in pancreatic ductal adenocarcinoma (PDAC) stroma compared to stroma from chronic pancreatitis. (**B**) Genes identified in the KEGG pathways, TS, tumour stroma; CP, stroma of chronic pancreatitis.](jcmm0012-2823-f2){#fig02}

Validation of differential expression of *WNT5a*, *CXCL14* and *SFRP1*
----------------------------------------------------------------------

We choose to validate the differential expression of *CXCL14*, *SFRP1* and *WNT5a* using quantitative RT-PCR and immunohistochemistry. The selection of those three genes was based on their assignment to important signal transduction pathways and on their differential expression. We could show that all genes, the underexpressed *SFRP1*, the only lightly overexpressed *WNT5a* and the highly overex-pressed *CXCL14* are differentially expressed in the stroma of PDACs compared to the stromal tissue of chronic pancreatitis. Quantitative RT-PCR showed that *SFRP1* is down-regulated by a fold change of 5.27, whereas *WNT5a* is up-regulated by a fold change of 2.06 and *CXCL14* is up-regulated by a fold change of 13.25 in the stroma of PDACs ([Fig. 3](#fig03){ref-type="fig"}). Using immunohistochemistry, we analysed stroma tissue from PDAC, peritumoural chronic pancreatitis or peritumour-al benign stromal tissue for the expression of *WNT5a*, *CXCL14* and *SFRP1*. For *WNT5a*, we detected an up-regulation in 92% of the cases (47/51, P \< 0.01, [Fig. 4A and B](#fig04){ref-type="fig"}). Analysis of the stromal tissue surrounding normal ducts revealed only rarely positive cells for *WNT5a*. Recently, it has been described that *WNT5a* is regulated by *CUTL1* in PDAC \[[@b31]\]. Analysis of the *CUTL1* expression in our gene expression data revealed mean arbitrary intensity units for *CUTL1* in tumour stroma of 251 and 252 in chronic pancreatitis stroma indicating that *CUTL1* is expressed in pancreatic stroma tissue, but not overexpressed. For CXCL14, an overexpression could be observed in 54% of the cases of PDAC-associated stroma compared to peritu-moural chronic pancreatitis tissue (7/13 [Fig. 4C and D](#fig04){ref-type="fig"}) and for SFRP1, we observed a loss of protein in stromal PDAC tissue in 65% of the cases analysed (24/37, [Fig. 4E and F](#fig04){ref-type="fig"}).

![Boxplots of the distribution of expression of *SFRP1*, WNT5a and *CXCL14* in stroma of PDAC and chronic pancreatitis. (**A**--**C**) Arbitrary intensity units of the probe sets from the Affymetrix U133 GeneChips; (**D**--**F**): Δ-cT values from the quantitative PCR, data were calculated as Δ-cT values using β-actin values for normalization, therefore lower values indicate higher expression of a given gene in the samples; (**G**) Relative expression of *WNT5a* in KIF5 stromal cells cocultured with Panc89 cells. *WNT5a* is induced in fibroblasts by a median of 2.82-fold if WNT5a expression is normalized to G6PDH expression and referred to the expression of WNT5a in KIF5 cells grown in monolayers; dotted lines: median; FC, fold change; TS, tumour stroma; CP, stroma of chronic pan-creatitis. *P*-values were calculated using the t-test.](jcmm0012-2823-f3){#fig03}

![Immunohistochemistry of Wnt pathway associated genes. (**A**) Strong expression of *WNT5a* in PDAC stroma cell and (**B**) lack of expression of *WNT5a* in stromal tissue adjacent to normal ducts in two different samples. The surrounding acinar cells of the pancreas show staining for *WNT5a*, whereas the normal duct epithelia show only a faint stain and staining is absent within the stromal cells; (**C**) *CXCL14* expression in PDAC epithelia and adjacent stromal cells. (**D**) Lack of expression of *CXCL14* in a stroma of chronic pancreatitis. (**E**) Expression of *SFRP1* in the stroma of chronic pancreatitis and blood vessels; (**F**) Loss of *SFRP1* expression in the stroma of a well-differentiated PDAC. (**A**--**F**) 200×.](jcmm0012-2823-f4){#fig04}

Induction of *WNT5a* by cocultivation
-------------------------------------

We also analysed three cell lines from stromal origin for their expression of the identified 331 probe sets. The stromal cell lines F13, Kif5 and Stellate, as well as the cell lines derived from PDAC tissues except PT45 expressed most of the genes in only low amounts under standard cultivation conditions ([Fig. 1C](#fig01){ref-type="fig"}). However, cocultivation of the human foreskin fibrob-last cell line Kif5 with the pancreas cancer cell line Panc89 resulted in a median 2.82-fold induction of *WNT5a* RNA in the fibroblasts. This indicates that *WNT5a* expression might be induced by soluble factors derived from pancreatic tumours, since the two cell lines were separated by a membrane with 0.2 μm pore size ([Fig. 3G](#fig03){ref-type="fig"}).

Discussion
==========

A strong desmoplastic reaction is typical for PDACs, but may also be found in other carcinomas, such as colon or breast carcinoma \[[@b32]--[@b34]\]. Since tumour desmoplasia seems to have an association with tumour progression, analysis of stromal gene expression may increase our understanding of this process. Using the Affymetrix U133 GeneChip set we performed the first whole genome gene expression analysis of microdissected cells from PDAC stroma and chronic pancreatitis stroma. Thus the tumour-specific stromal reaction can be discriminated from the severe, but benign reaction represented by chronic pancreatitis. We identified 316 differentially expressed genes represented by 331 Affymetrix probe sets, of which 255 were up-regulated and 61 genes down-regulated in the stromal tissue of PDAC compared to chronic pancreatitis stroma. Within the set of genes up-regulated in PDAC stromal tissue, we identified *MMP11* and *CXCL14* which has been shown to be activated in stromal tissue other carcinomas \[[@b35]--[@b37]\]. Despite the importance of the stromal tissue for tumour development and maintenance, few gene expression studies on stromal tissue have been performed. This might be due to the fact that microdissection is a prerequisite for profiling stromal tissue. We compared our data with the data set published by Binkley *et al*. and found an overlap of six genes (*COL10A1*, *COL4A2*, *IFI30*, *IFI6*, *POSTN* and *UCP2*) \[[@b38]\]. The reason for this small overlap might be found in the different types of analysis. Binkley et al. used a bioin-formatic approach to identify stromal gene expression by subtracting epithelial gene expression data from their data of pancreatic cancer gene expression; whereas, we analysed the gene expression of tumours stroma directly. The different GeneChip formats might also be another cause for the small overlap, we observed as Binkley *et al*. analysed only 6800 human genes, whereas we analysed of the whole human transcriptome (∼30,000 genes). Of the 61 genes underex-pressed in PDAC stroma, some are highly expressed in normal epithelia. This might be owed to spurious epithelial cells within the stroma of chronic pancreatitis which cannot be eliminated by manual microdissection. However, the immunohistochemical validation of *WNT5a*, *SFRP1* and *CXCL14* clearly demonstrates that the genes identified by our approach are differentially expressed between *PDAC* and chronic pancreatitis stroma.

We classified the genes according to their involvement in signal transduction pathways and found a high proportion of Wnt pathway members as dysregulated suggesting that this pathway plays a role in stroma--tumour interaction in PDACs. Interestingly, we found a down-regulation of *SFRP1* in PDAC stroma. As it has been shown that *SFRP1* expression is lost by hypermethylation in the majority of cancers and PDACs \[[@b39], [@b40]\], this is the first report of the down-regulation of SFRP1 in primary stromal tissue. We may speculate that *SFRP1* down-regulation in PDAC stroma is linked to hypermethylation of the *SFRP1* gene in PDAC stroma as observed in cancer epithelia. *SFRP1* is an inhibitor of canonical Wnt action and it is also capable of transducing signals without the participation of Wnt molecules *via* Frizzled receptors \[[@b41]\]. As *WNT5a* is known to be able to inactivate the canonical pathway, our observed overexpression of *WNT5a* in the stromal and the epithelial compartment of PDAC might be a reason for the dormancy of the canonical Wnt pathway \[[@b42]\]. *WNT5a* has been shown to activate *MMP7* and to enhance the invasiveness of breast cancer cells *via* the non-canonical JNK pathway which might also occur in PDAC stroma, since we observed a *MMP7* overexpression in those cells \[[@b43]\]. Interestingly, in PDAC cells *WNT5a* might also promote growth and invasion \[[@b31]\] indicating that the stromal compartment might contribute to these processes. However, despite the overexpression of *WNT5a* in PDAC stromal tissue we did not observe an overexpression of *CUTL1* suggesting that also other signalling pathways might contribute to the transcriptional activation of *WNT5a* and may act *via* soluble factors as the induction of *WNT5a* expression in fibroblasts demonstrated. These factors are most likely proteins of the hedgehog family, which are overexpressed in PDAC and known to regulate *WNT5a* expression \[[@b44], [@b45]\]. *WNT5a* has also been characterized as a modulator of chondrocyte development and associated with chondrocyte hyper-trophy \[[@b46]\]. Chondrocyte hypertrophy is also associated with the expression of COL10A1 \[[@b47]\] which we and others identified to be overexpressed in PDAC stroma \[[@b38]\]. Therefore, *WNT5a* overexpres-sion in tumour stroma might result in overexpression of *COL10A1*. *COL10A1* belongs to the type of network-forming collagens; whereas, *COL11A1* which we also observed as overexpressed in PDAC stroma is a fibrillar collagen \[[@b48]\]. The overexpression of these two types of collagen might have profound effects on the density of the extracellular matrix surrounding the PDAC cells and might contribute to the callous form of tumours seen in PDAC. Gene expression profiling of microdissected tissues has been shown feasible and generates a complete picture of changes not only in the tumour epithelia \[[@b49]\], but also as shown here in the stromal tissue surrounding the tumour. The differential expression we have observed in our data might therefore lead to a better understanding of the generation of desmoplasia in PDAC.
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